121,623 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC purchased a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 121,623 shares of the biotechnology company's stock, valued at approximately $1,678,000. Voloridge Investment Management LLC owned about 0.27% of Capricor Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. increased its stake in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Invesco Ltd. grew its stake in shares of Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after buying an additional 2,500 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Finally, Corebridge Financial Inc. grew its stake in shares of Capricor Therapeutics by 32.2% in the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock valued at $251,000 after buying an additional 4,434 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Down 0.9%

NASDAQ CAPR traded down $0.09 during mid-day trading on Friday, reaching $10.00. 2,087,187 shares of the company's stock traded hands, compared to its average volume of 1,748,505. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a fifty day simple moving average of $10.21 and a 200-day simple moving average of $13.14. The company has a market cap of $456.77 million, a price-to-earnings ratio of -9.43 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter last year, the business earned ($0.31) EPS. Equities research analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Roth Capital assumed coverage on Capricor Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $31.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.